AR120867A1 - Tratamiento combinado de enfermedades hepáticas con inhibidores de integrina - Google Patents

Tratamiento combinado de enfermedades hepáticas con inhibidores de integrina

Info

Publication number
AR120867A1
AR120867A1 ARP200103605A ARP200103605A AR120867A1 AR 120867 A1 AR120867 A1 AR 120867A1 AR P200103605 A ARP200103605 A AR P200103605A AR P200103605 A ARP200103605 A AR P200103605A AR 120867 A1 AR120867 A1 AR 120867A1
Authority
AR
Argentina
Prior art keywords
liver diseases
integrine
inhibitors
combined treatment
therapeutic agent
Prior art date
Application number
ARP200103605A
Other languages
English (en)
Inventor
Kraig Anderson
Christopher Bailey
Avirup Bose
Jacob Cha
Nicole Cooper
Darren Finkelstein
Linda Greenbaum
Johannes Hull
Susan Kirkland
Katerina Leftheris
Maureen Reily
Peter Tarsa
Chinweike Ukomadu
Original Assignee
Novartis Ag
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Pliant Therapeutics Inc filed Critical Novartis Ag
Publication of AR120867A1 publication Critical patent/AR120867A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente es una combinación farmacéutica que incluye un inhibidor de integrina aVb₁ y por lo menos un agente terapéutico adicional para la prevención, retardo o tratamiento de enfermedades o trastornos hepáticos. El agente terapéutico adicional puede ser un inhibidor del SGLT1/2, entre una diversa selección de agentes. Por ejemplo, la combinación farmacéutica incluye el ácido (S)-2-(4-metiltetrahidro-2H-piran-4-carboxamido)-9-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)nonanoico (Compuesto 1) y por lo menos un agente terapéutico adicional.
ARP200103605A 2019-12-20 2020-12-21 Tratamiento combinado de enfermedades hepáticas con inhibidores de integrina AR120867A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962951600P 2019-12-20 2019-12-20

Publications (1)

Publication Number Publication Date
AR120867A1 true AR120867A1 (es) 2022-03-23

Family

ID=74186952

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103605A AR120867A1 (es) 2019-12-20 2020-12-21 Tratamiento combinado de enfermedades hepáticas con inhibidores de integrina

Country Status (11)

Country Link
US (1) US20230060422A1 (es)
EP (1) EP4076454A1 (es)
JP (1) JP2023507364A (es)
KR (1) KR20220119424A (es)
CN (1) CN114929218A (es)
AR (1) AR120867A1 (es)
AU (1) AU2020408067B2 (es)
CA (1) CA3164941A1 (es)
IL (1) IL293894A (es)
TW (1) TW202135811A (es)
WO (1) WO2021127466A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023008330A (es) 2021-01-20 2024-01-18 Viking Therapeutics Inc Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
CN104513213A (zh) 2013-09-28 2015-04-15 山东亨利医药科技有限责任公司 Fxr激动剂
CA2942403A1 (en) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Fxr agonists and methods for making and using
WO2016081918A1 (en) 2014-11-21 2016-05-26 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
MX369623B (es) 2014-12-22 2019-11-14 Akarna Therapeutics Ltd Compuestos biciclicos fusionados para el tratamiento de enfermedades.
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
MX2017015690A (es) 2015-06-05 2018-07-06 Novartis Ag Anticuerpos dirigidos a la proteina morfogenetica osea 9 (bmp9) y metodos a partir de estos.
EP3331914A1 (en) 2015-08-03 2018-06-13 Novartis AG Methods of treating fgf21-associated disorders
WO2017078928A1 (en) 2015-11-06 2017-05-11 Salk Institute For Biological Studies Fxr agonists and methods for making and using
ES2806276T3 (es) * 2015-12-30 2021-02-17 Univ Saint Louis Derivados de ácido aminobenzoico meta-azaciclicos como antagonistas pan-integrina
CN106946867B (zh) 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
WO2017128896A1 (zh) 2016-01-26 2017-08-03 江苏豪森药业集团有限公司 Fxr激动剂及其制备方法和应用
WO2017143134A1 (en) 2016-02-19 2017-08-24 Alios Biopharma, Inc. Fxr modulators and methods of their use
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
JP6678779B2 (ja) 2016-06-13 2020-04-08 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒ（ｎｒ１ｈ４）調節化合物
US10183872B2 (en) 2016-06-13 2019-01-22 Qi Wang Counter circulating liquid processing system by repeatedly re-using thermal energy
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
US11091482B2 (en) 2016-08-23 2021-08-17 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
EP3509590A4 (en) * 2016-09-07 2020-12-02 Pliant Therapeutics, Inc. N-ACYL AMINO ACID COMPOUNDS AND METHOD OF USING
WO2018059314A1 (zh) 2016-09-28 2018-04-05 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
KR20190056436A (ko) 2016-10-04 2019-05-24 이난타 파마슈티칼스, 인코포레이티드 Fxr 작용제로서의 이속사졸 유사체 및 그의 사용 방법
CN107973790A (zh) 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
CN108017636A (zh) 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
CN109071468B (zh) 2017-01-20 2022-09-02 四川科伦博泰生物医药股份有限公司 一种杂环化合物及其制备方法和用途
AU2018218557B9 (en) 2017-02-08 2021-06-24 Novartis Ag FGF21 mimetic antibodies and uses thereof
WO2018190643A1 (en) 2017-04-12 2018-10-18 Il Dong Pharmaceutical Co., Ltd. An isoxazole derivatives as nuclear receptor agonists and used thereof
EP3632910A4 (en) 2017-05-26 2021-02-24 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. LACTAM COMPOUND AS FXR RECEPTOR AGONIST
JP2020524684A (ja) * 2017-06-21 2020-08-20 ノバルティス アーゲー 非アルコール性脂肪性肝炎の治療のためのリコフリゴジン
BR112020000180A2 (pt) 2017-07-06 2020-07-14 Xuanzhu (Hainan) Biopharmaceutical Co., Ltd. agonista do receptor fxr
US11292802B2 (en) * 2017-11-07 2022-04-05 Bristol-Myers Squibb Company Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors
CA3093225A1 (en) * 2018-03-07 2019-09-12 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
IL279717B2 (en) * 2018-06-27 2024-05-01 Pliant Therapeutics Inc Amino acid compounds with non-branched linkers and methods of use
CN109053751A (zh) 2018-08-30 2018-12-21 成都海博锐药业有限公司 具有螺环结构的fxr调节剂

Also Published As

Publication number Publication date
AU2020408067B2 (en) 2024-03-28
WO2021127466A1 (en) 2021-06-24
JP2023507364A (ja) 2023-02-22
KR20220119424A (ko) 2022-08-29
TW202135811A (zh) 2021-10-01
EP4076454A1 (en) 2022-10-26
CA3164941A1 (en) 2021-06-24
US20230060422A1 (en) 2023-03-02
AU2020408067A1 (en) 2022-06-30
IL293894A (en) 2022-08-01
CN114929218A (zh) 2022-08-19

Similar Documents

Publication Publication Date Title
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
NI202100009A (es) Métodos para reducir la necesidad de revascu
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
CL2019000821A1 (es) Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
ES2497494T3 (es) Método de tratamiento y prevención del hiperparatiroidismo secundario
CL2017002904A1 (es) Métodos y kits para tratar la depresión
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
MX2020009757A (es) Producto combinado de inhibidor de bcl-2 e inhibidor de mdm2 y uso de este en la prevencion y/o tratamiento de enfermedades.
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
DOP2012000290A (es) 4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer utero y cancer de ovario
CL2012001583A1 (es) Preparación oftálmica que comprende: a) povidona yodada, b) un agente refrescante y c) uno o más entre alcanfor, borneol, lubricante, emoliente, antiinflamatorio esteroidal y antinflamatorio no esteroidal; y su uso para el tratamiento y/o profilaxis de un trastorno ocular o una infección.
CO2019013047A2 (es) Composiciones sólidas para administración oral
CO2021005070A2 (es) Inhibición de la proteasa 30 específica de la ubiquitina (usp30)
CO2024000588A2 (es) Composiciones y métodos para la inhibición de ras
CL2021001536A1 (es) 3,3- difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que las comprenden
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CL2021001956A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables. (divisional solicitud 202002624)
MX2020004179A (es) Combinacion que comprende al menos un modulador de espliceosomas y al menos un inhibidor elegido de inhibidores de bcl2, bcl2/bclxl y bclxl, y metodos de uso.
CL2019001304A1 (es) Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica.
CL2022000214A1 (es) Inhibidores de enzimas
AR120867A1 (es) Tratamiento combinado de enfermedades hepáticas con inhibidores de integrina
ECSP17010817A (es) Métodos y composiciones para el tratamiento de trastornos relacionados con vih
CL2022002531A1 (es) Moduladores de nlrp3
AR112291A1 (es) Composición para su uso en la prevención y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncológico

Legal Events

Date Code Title Description
FB Suspension of granting procedure